Compounded
Tirzepatide

Tirzepatide is a medication that acts on GIP and GLP-1 receptors. This product is a compounded oral Tirzepatide formulation. Compounded oral Tirzepatide is not FDA-approved, and FDA has not reviewed this formulation or route of administration for safety, effectiveness, quality, or bioavailability. A licensed healthcare provider will determine whether a compounded formulation is medically necessary and appropriate for you.

Tirzepatide acts on GIP and GLP-1 receptors, which help regulate blood sugar and appetite by supporting insulin release, slowing digestion, and may help with feelings of fullness. The absorption, systemic exposure, and clinical effects of compounded oral Tirzepatide have not been evaluated or approved by the FDA and may differ from FDA-approved injectable formulations.

Compounded oral lozenge Tirzepatide: When using a Tirzepatide lozenge, you will likely be instructed to use one every day, once a day, at approximately the same time. This is a buccal lozenge, so you will not swallow the lozenge, but let it slowly dissolve between your gum and cheek to absorb the medication. Your provider may also recommend changes to nutrition, physical activity, and other lifestyle measures as part of your overall weight-management plan. If you have any questions on your dosage, contact your healthcare provider for more information.

Individual response to compounded oral Tirzepatide may vary. The timing and extent of absorption and clinical response with an oral compounded formulation have not been established through FDA review. If you are not receiving the desired result, please let your provider know. Your provider will monitor your response and determine what adjustments are appropriate.

Use compounded oral Tirzepatide according to the dosing schedule on your prescription label. Take it at approximately the same time each day unless instructed otherwise. Do not take additional doses or change your dosing schedule without speaking with your healthcare provider.

Tell your provider about all medical conditions and medications you take before starting treatment. This is particularly important if you have had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); a history of pancreatitis, gallbladder disease, kidney problems, severe gastrointestinal disease or gastroparesis, diabetes or diabetic retinopathy; or if you use insulin or medications that may lower blood sugar. Tell your provider if you are pregnant, planning pregnancy, breastfeeding, or use oral hormonal contraception. The safety profile of compounded oral Tirzepatide has not been established through FDA review.

Do not use other Tirzepatide-containing products or GLP-1 receptor agonists unless specifically directed by your provider. Tell your provider about all prescription medications, over-the-counter medications, vitamins, and supplements you take. Avoid high-fat foods, foods with lots of added sugar, trans and saturated fats, processed carbohydrates, and foods with high sodium as they may cause intestinal discomfort. Tirzepatide can affect gastric emptying, which may affect absorption of certain oral medications with FDA-approved injectable treatment. It is not known whether the same effect occurs to the same extent with compounded oral Tirzepatide.

The most common side effects of Tirzepatide involve your digestion and gastrointestinal tract. Nausea, diarrhea, vomiting, constipation, dyspepsia, abdominal pain, fatigue, hypersensitivity reactions, burping, hair loss, and gastroesophageal reflux disease (GERD) may occur. Other common side effects may include headache, dizziness, tiredness, and low blood sugar levels in people who have diabetes. Because compounded oral Tirzepatide has not been FDA-approved or evaluated for safety, effectiveness, quality, or bioavailability, its adverse-effect profile and frequency of side effects are not established. Contact us if you experience persistent or concerning symptoms. For a full list of the possible side effects of Tirzepatide, including the less common but more serious side effects, look at the patient safety information on our website and the Tirzepatide package information.